Astellas
Astellas says the old and new NDCs for its antifungal drug Cresemba are interchangeable in compliant 340B inventory replenishment models.

Astellas Notifies 340B Entities About Antifungal’s Updated NDC

Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company says in a public notice.

The U.S. Health Resources and Services Administration posted Astellas’ notice on the HRSA website last week. The company updated Cresemba’s NDC on Nov. 14. The medicine is used to treat rare mold infections that usually affect only people with weakened immune systems.

Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company says in a public notice.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts